These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33986067)

  • 1. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
    BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
    Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
    J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries.
    Kowada A
    Travel Med Infect Dis; 2016; 14(5):489-498. PubMed ID: 27238907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
    Wheeler C; Mohle-Boetani J
    Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study.
    Alvarez GG; Van Dyk D; Mallick R; Lesperance S; Demaio P; Finn S; Potvin SE; Patterson M; Pease C; Amaratunga K; Hui C; Cameron DW; Mulpuru S; Aaron SD; Momoli F; Zwerling A
    Int J Circumpolar Health; 2020 Dec; 79(1):1758501. PubMed ID: 32379538
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
    Lai WA; Brethour K; D'Silva O; Chaisson RE; Zwerling AA
    BMC Public Health; 2022 Dec; 22(1):2292. PubMed ID: 36476206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.
    Moro RN; Borisov AS; Saukkonen J; Khan A; Sterling TR; Villarino ME; Scott NA; Shang N; Kerrigan A; Goldberg SV
    Clin Infect Dis; 2016 Jun; 62(11):1390-1400. PubMed ID: 26951571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
    Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
    AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
    Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
    Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM; Jalees M; Lam C; Burzynski J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.